ReviewMemo2018
Pitfalls in the radiological response assessment of immunotherapy.
Review in Memo, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 2 syntheses or guidelines pooled it, 76 citations in OpenAlex.
- Hyperprogressive disease in carcinoma induced by immune checkpoint inhibitor therapy: a systematic review.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Pooled it
- The combined use of steroids and immune checkpoint inhibitors in brain metastasis patients: a systematic review and meta-analysis.Neuro-oncology · 2021Pooled it
- Immune imitation of tumor progression after anti-CD19 chimeric antigen receptor T cells treatment in aggressive B-cell lymphoma.Bone marrow transplantation · 2021Trial
- Early objective response to avelumab treatment is associated with improved overall survival in patients with metastatic Merkel cell carcinoma.Cancer immunology, immunotherapy : CII · 2019Trial
- The potential survival gain and cost-effectiveness of circulating tumor DNA-guided treatment switching in advanced non-small cell lung cancer: A simulation modeling study.The journal of liquid biopsy · 2026Article
- Advancing In Vivo Detection of T-Cell Function: Development and Preclinical Evaluation ofJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2025Article
- Delta-radiomics in cancer immunotherapy response prediction: A systematic review.European journal of radiology open · 2023Article
- Article
- Imaging Follow-Up of Nonsurgical Therapies for Lung Cancer:AJR. American journal of roentgenology · 2023Review
- Early changes in soluble intracellular adhesion molecule-1 as prognostic biomarkers to immune checkpoint inhibitor.Clinical and translational science · 2023Article
- The radiological appearances of lung cancer treated with immunotherapy.The British journal of radiology · 2023Review
- Management of Non-Melanoma Skin Cancer: Radiologists Challenging and Risk Assessment.Diagnostics (Basel, Switzerland) · 2023Review
- Article
- Management of cutaneous melanoma: radiologists challenging and risk assessment.La Radiologia medica · 2022Review
- New Challenges in Evaluating Outcomes after Immunotherapy in Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma.Vaccines · 2022Article
- Coexisting opportunities and challenges: In which scenarios can minimal/measurable residual disease play a role in advanced non-small cell lung cancer?Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2021Article
- Toripalimab in an advanced non-small cell lung cancer patient with poor general condition after multiline treatment: a case report.The Journal of international medical research · 2021Article
- Assessment of early metabolic progression in melanoma patients under immunotherapy: anEJNMMI research · 2021Article
- Article
- Pseudoprogression and hyperprogression in lung cancer: a comprehensive review of literature.Journal of cancer research and clinical oncology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immunotherapies comprise of a class of cancer therapies that are increasingly used for treatment of several cancer entities. Active immunotherapies encompassing immune checkpoint inhibitors are the most widespread class of immunotherapies, with indications for melanoma, non-small lung cancer, renal cell carcinoma, urothelial carcinoma, head and neck squamous cell carcinoma, and Hodgkin's lymphoma. Immune checkpoint inhibitors have demonstrated unique response patterns that are not adequately captured by traditional response criteria such das the Response Evaluation Criteria in Solid Tumors (RECIST) and World Health Organization criteria. Consequently, adaptions of these criteria have been released such as the immune-related RECIST and immune RECIST, which account for the specialities of immunotherapies. Immunotherapies can cause a distinct set of adverse events such as pneumonitis, colitis, and hypophysitis. In addition, atypical treatment response patterns termed pseudoprogression have been observed. Thereby, new or enlarging lesions appear after treatment start and mimic tumor progression, which is followed by an eventual decrease in total tumor burden. In this review article we will describe pitfalls in the radiological response assessment of immunotherapies, focusing on pseudoprogression and imaging appearances of common immune-related adverse events.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.